Feedback

Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches

ORCID
0000-0002-6996-0443
Affiliation
Epidemiology and Biostatistics Group, Research Group in Educational Statistics, National University of Education (UNAE), Azogues 030102, Ecuador
Ramírez-Coronel, Andrés Alexis;
Affiliation
Department of Internal Medicine, Faculty of General Medicine, Yerevan State Medical University, Yerevan 375010, Armenia
Rostami, Amirabbas;
Affiliation
Department of Clinical Laboratory Sciences, Faculty of Pharmacy, Jabir Ibn Hayyan Medical University, Al Najaf Al Ashraf 54001, Iraq
Younus, Laith A.;
Affiliation
Pontificia Universidad Católica Del Peru, Lima 15001, Peru
Arias Gonzáles, José Luis;
Affiliation
Iraqi Ministry of Education, Baghdad 10011, Iraq
Lafta, Methaq Hadi;
Affiliation
Deanship of Scientific Research, Umm Al-Qura University, Makkah 21955, Saudi Arabia
Amin, Ali H.;
Affiliation
Directorate General of Education Karkh 1, Ministry of Education, Baghdad 10011, Iraq
Saadoon, Mohammed Abdulkadhim;
Affiliation
Department of Computer Science, Al-Turath University College Al Mansour, Baghdad 10011, Iraq
Salman, Hayder Mahmood;
ORCID
0000-0001-7330-4134
Affiliation
Biomedical Center for Systems Biology Science Munich, Ludwig-Maximilians-University, 80333 Munich, Germany
Bahrami, Abolfazl;
Affiliation
Department of Cell Biology, Tuebingen University, 72072 Tuebingen, Germany
Feilei, Rossa;
Affiliation
Department of Neurosurgery, University Medical Center, 72072 Tuebingen, Germany
Akhavan-Sigari, Reza

Recurrent pregnancy loss (RPL) occurs in approximately 5% of women. Despite an abundance of evidence, the molecular mechanism of RPL’s pathology remains unclear. Here, we report the protective role of polo-like kinase 1 (PLK1) during RPL. We aimed to construct an RPL network utilizing GEO datasets and identified hub high-traffic genes. We also investigated whether the expressions of PLK1 were altered in the chorionic villi collected from women with RPL compared to those from healthy early pregnant women. Gene expression differences were evaluated using both pathway and gene ontology (GO) analyses. The identified genes were validated using in vivo and in vitro models. Mice with PLK1-overexpression and PLK1-knockdown in vitro models were produced by transfecting certain plasmids and si-RNA, respectively. The apoptosis in the chorionic villi, mitochondrial function, and NF-κB signaling activity was evaluated. To suppress the activation of PLK1, the PLK1 inhibitor BI2536 was administered. The HTR-8/SVneo and JEG-3 cell lines were chosen to establish an RPL model in vitro. The NF-κB signaling, Foxo signaling, PI3K/AKT, and endometrial cancer signaling pathways were identified via the RPL regulatory network. The following genes were identified: PLK1 as hub high-traffic gene and MMP2 , MMP9 , BAX , MFN1 , MFN2 , FOXO1 , OPA1 , COX15 , BCL2 , DRP1 , FIS1 , TRAF2 , and TOP2A . Clinical samples were examined, and the results demonstrated that RPL patients had tissues with decreased PLK1 expression in comparison to women with normal pregnancies ( p < 0.01). In vitro, PLK1 knockdown induced the NF-κB signaling pathway and apoptosis activation while decreasing cell invasion, migration, and proliferation ( p < 0.05). Furthermore, the in vivo model proved that cell mitochondrial function and chorionic villi development are both hampered by PLK1 suppression. Our findings revealed that the PLK1/TRAF2/NF-κB axis plays a crucial role in RPL-induced chorionic villi dysfunction by regulating mitochondrial dynamics and apoptosis and might be a potential therapeutic target in the clinic.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © 2023 by the authors.

Use and reproduction: